BALTIMORE--(BUSINESS WIRE)--May 12, 2006--Osiris Therapeutics, Inc. announced today that the Company has filed a registration statement with the U.S. Securities and Exchange Commission relating to the proposed initial public offering of its common stock. The number of shares to be offered and the price range for the offering have not yet been determined. All shares of the common stock to be sold in this offering will be offered by the Company.
Deutsche Bank Securities Inc. will be acting as the sole book-running manager for the offering. This offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to the offering may be obtained from Deutsche Bank Securities Inc., 60 Wall Street, New York, NY 10005, Attention: Syndicate Department.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.
About Osiris Therapeutics
Osiris Therapeutics, Inc. is a leading stem cell therapeutic company focused on developing and marketing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas. Osiris currently markets and sells Osteocel® for regenerating bone in orthopedic indications. Prochymal(TM) is entering Phase III clinical trials and is the first stem cell therapeutic to receive FDA Fast Track and Orphan Drug designations. The Company’s pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen(TM) for regenerating cartilage in the knee, and Provacel(TM), for repairing heart tissue following a heart attack. Osiris is a fully integrated company, having developed stem cell capabilities in research and development, manufacturing, marketing and distribution. Osiris has developed an extensive intellectual property portfolio to protect the company’s technology in the United States and a number of foreign countries including 45 U.S. and 132 foreign patents owned or licensed.
Contact: Osiris Therapeutics, Inc. Lisa Rodemann, 410-522-5005, extension 610
Source: Osiris Therapeutics, Inc.
